New Report Unveils Hottest Industry Trends in Life Sciences Sector 2014
george james Ltd, a leading provider of recruitment, training and corporate development services to the scientific industry, has announced the availability of a new report “Life Science Trends 2014,” which outlines trends and innovations in the life sciences industry. Written in conjunction with Carlyle Conlan, the report encompasses drugs, biologics, devices and diagnostics sectors, summarising a variety of the most up to date industry news. It demonstrates significant advances in the industry from the past year and highlights observations about developments of interest throughout the year ahead. To obtain a free copy of the report please click here.
Designed as a meaningful “quick read” whitepaper, the report is separated into several macro headers: Research and Innovation, Fundamental Trends, Investing and Deal Making, Regulatory and Government and Health Care. The report is essential reading for those working in the pharmaceutical and biotech industries who are not only looking for an overall summary, but a resource to explore deeper, dependant on the individual interest of the reader.
In addition, the essential annual report also includes an exclusive feature article “Big Data in the Life Sciences”, which highlights commentary and interviews from several key senior industry professionals involved in big data breakthroughs in the life sciences sector. This feature article demonstrates how the enormous increase in data volume from segments like sequencing and systems biology, coupled with trends in pre-competitive data sharing and advanced computing frameworks, is in the early stages of providing robust signals, that will ultimately decrease the cost of drug development and maximise the industry’s return on investment.
Neil Burns, Founding Director at george james Ltd, said: “We are very pleased that this report has been published and is now easily available to download from our website. It has been structured in a way which is easy to read for industry professionals in pharma and biotech to keep informed but still can be researched further. We at george james strive help our customers achieve their core goals and specialisation and hope this report offers premium research of value to the life sciences sector.”
Don Alexander, Practice Head and Vice President, Life Sciences at Carlyle Conlan, comments: “We are very pleased to be able to, with the support of George James, have a report available for the public to read which covers such a wide range of articles across pertinent areas such as Health Care, Research and Innovation. What makes our report different is that an early version is sent to CEOs, venture capitalists and other industry experts for review before its final release and created using both primary and secondary data. We invite you to review the information contained in the report which we hope you will find relevant and interesting.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance